Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy

被引:29
作者
Birk, M
Svedhem, V
Sönnerborg, A
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden
[3] Karolinska Hosp, Div Infect Dis, S-10401 Stockholm, Sweden
关键词
antiretroviral therapy; drug resistance; HIV-1; rebound; viral load;
D O I
10.1097/00002030-200107270-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To study the kinetics of HIV-1 RNA and drug-induced mutations after cessation of anti retroviral therapy (ART). Design and methods: Successive plasma samples from 26 patients were tested for HIV-1 RNA by PCR and for mutations associated with drug resistance by sequencing of the pol gene. Results: After cessation of ART the phase of undetectable virus (< 50 copies/ml), ranging from 6 to more than 29 days, was followed by a rapid viral increase, which slowed down before a plateau corresponding to pre-treatment levels or higher was reached in most cases (14/19 patients). In one patient virus was still undetectable at 4 weeks. Also, a significantly larger number of primary protease inhibitor (PI)-associated mutations reverted to wild-type, as compared with secondary PI-, and primary reverse transcriptase inhibitor (RTI)-associated mutations. During the rapid viral increase no mutations disappeared, which instead happened during the slower viral increase preceding the viral plateau level. Conclusion: After discontinuation of ART large individual Variations were found for the time period until HIV-1 became detectable in plasma, possibly due to differences in the HIV-1 specific immunity. The more rapid loss of primary PI mutations suggests that they might cause a more impaired viral fitness than primary RTI mutations. However, the persistence of drug mutations during the initial viral load increase indicates that mutated strains may still replicate efficiently (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1359 / 1368
页数:10
相关论文
共 36 条
[21]   Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication [J].
Ioannidis, JPA ;
Havlir, DV ;
Tebas, P ;
Hirsch, MS ;
Collier, AC ;
Richman, DD .
AIDS, 2000, 14 (11) :1481-1488
[22]   Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen [J].
Izopet, J ;
Massip, P ;
Souyris, C ;
Sandres, K ;
Puissant, B ;
Obadia, M ;
Pasquier, C ;
Bonnet, E ;
Marchou, B ;
Puel, J .
AIDS, 2000, 14 (15) :2247-2255
[23]   Control of HIV despite the discontinuation of antiretroviral therapy [J].
Lisziewicz, J ;
Rosenberg, E ;
Lieberman, J ;
Jessen, H ;
Lopalco, L ;
Siliciano, R ;
Walker, B ;
Lori, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) :1683-1684
[24]   Viral dynamics of acute HIV-1 infection [J].
Little, SJ ;
McLean, AR ;
Spina, CA ;
Richman, DD ;
Havlir, DV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (06) :841-850
[25]   Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure [J].
Miller, V ;
Sabin, C ;
Hertogs, K ;
Bloor, S ;
Martinez-Picado, J ;
D'Aquila, R ;
Larder, B ;
Lutz, T ;
Gute, P ;
Weidmann, E ;
Rabenau, H ;
Phillips, A ;
Staszewski, S .
AIDS, 2000, 14 (18) :2857-2867
[26]   HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment [J].
Neumann, AU ;
Tubiana, R ;
Calvez, V ;
Robert, C ;
Li, TS ;
Agut, H ;
Autran, B ;
Katlama, C .
AIDS, 1999, 13 (06) :677-683
[27]   Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy [J].
Ogg, GS ;
Jin, X ;
Bonhoeffer, S ;
Moss, P ;
Nowak, MA ;
Monard, S ;
Segal, JP ;
Cao, Y ;
Rowland-Jones, SL ;
Hurley, A ;
Markowitz, M ;
Ho, DD ;
McMichael, AJ ;
Nixon, DF .
JOURNAL OF VIROLOGY, 1999, 73 (01) :797-800
[28]   Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].
Palella, FJ ;
Delaney, KM ;
Moorman, AC ;
Loveless, MO ;
Fuhrer, J ;
Satten, GA ;
Aschman, DJ ;
Holmberg, SD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860
[29]   Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption [J].
Papasavvas, E ;
Ortiz, GM ;
Gross, R ;
Sun, JW ;
Moore, EC ;
Heymann, JJ ;
Moonis, M ;
Sandberg, JK ;
Drohan, LA ;
Gallagher, B ;
Shull, J ;
Nixon, DF ;
Kostman, JR ;
Montaner, LJ .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (03) :766-775
[30]   Decay characteristics of HIV-1-infected compartments during combination therapy [J].
Perelson, AS ;
Essunger, P ;
Cao, YZ ;
Vesanen, M ;
Hurley, A ;
Saksela, K ;
Markowitz, M ;
Ho, DD .
NATURE, 1997, 387 (6629) :188-191